- Allurion Technologies (ALUR, Financial) presents positive study results on weight loss and muscle gain with their Allurion Program in France.
- Data from 1,962 patients shows a notable muscle mass increase by 6.6% and fat mass reduction by 11% over four months.
- Shipments to France have resumed, with patient treatments expected to restart next month.
Allurion Technologies, Inc. (ALUR), a leader in metabolically healthy weight loss solutions, unveiled promising results at the recent SOFFCO.MM meeting in France. The study focused on the Allurion Program, which combines the innovative Swallowable Gastric Balloon and AI-driven health coaching, showing significant improvements in patients' body composition.
In a cohort of 1,962 patients in France, muscle mass as a percentage of total body weight increased by 6.6%, while fat mass decreased by 11%. Additionally, there was an average reduction in total body weight by 12.2% over four months, and visceral fat index showed a notable decrease of 12.2%.
The presentation by Allurion underscores the potential for sustainable, long-term weight management through improvements in muscle mass and fat reduction. This approach aims to not only aid in weight loss but also enhance metabolic health.
Amidst this development, Allurion has announced the resumption of shipments to France, with patient treatments scheduled to restart the following month. The company's CEO, Dr. Shantanu Gaur, expressed enthusiasm about re-entering the French market, highlighting the expected benefits for both providers and patients.
Allurion Technologies continues to advance its presence in the medical devices sector, focusing on innovative approaches to weight loss and health improvement. For more details on the Allurion Program and the company's offerings, visit their official website.
